Literature DB >> 9697078

Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

M Tod1, P Alet, O Lortholary, O Petitjean.   

Abstract

A stochastic control strategy for individualizing teicoplanin dosing schedule in neutropenic patients is proposed and compared to the usual Bayesian approach based on the mode of the posterior density of the model parameters. Teicoplanin disposition is described by a bicompartmental model. Age, body weight, serum creatinine, white blood cell count, and sex can be included as covariates. Posterior density of model parameters is obtained by Bayes theorem under a discrete form from which the posterior density of teicoplanin trough concentrations are computed for any dosing schedule. Optimal maintenance dose is determined by minimizing the cost associated, through a logarithmic risk function, to the concentrations being outside the therapeutic range. In Monte Carlo simulation studies on 300 individuals, stochastic control was more accurate than, and equally precise as the usual Bayesian approach. Two-sample based predictions were not better than one-sample based ones. Inclusion of covariates in the model improved dramatically the performances of both strategies. A small retrospective study based on real data (n = 16 patients) shows that reasonable accuracy (bias of 0.7 mg/L) and precision (3 mg/L) in teicoplanin trough concentration prediction is obtained with both strategies provided that covariates are taken into account.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9697078     DOI: 10.1023/a:1025729817252

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  Bayesian individualization via sampling-based methods.

Authors:  J Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

2.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics.

Authors:  D Katz; D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

5.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

6.  Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach.

Authors:  N Taright; F Mentré; A Mallet; R Jouvent
Journal:  Ther Drug Monit       Date:  1994-06       Impact factor: 3.681

7.  Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters, and pharmacostatistical model.

Authors:  Y Tanigawara; I Yano; K Kawakatsu; K Nishimura; M Yasuhara; R Hori
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

8.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.

Authors:  J A Smithers; H K Kulmala; G A Thompson; K K Antony; E W Lewis; S J Ruberg; M T Kenny; J K Dulworth; M A Brackman
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

10.  A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.

Authors:  D Greenwood; K Bidgood; M Turner
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

View more
  2 in total

1.  A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Authors:  Michaël Philippe; Michael Neely; Yves Bertrand; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 2.  Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

Authors:  M M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.